ADM expands probiotics production ‘five-fold’ with new Spanish facility

By Will Chu

- Last updated on GMT


Related tags Adm Valencia Probiotic

US ingredient giants ADM are to expand its microbiome-related production activities five-fold with the creation of a European facility that is expected to be in operation in 2022.

The facility, to be based in Valencia, Spain, will be co-located alongside ADM’s flavour production facility also in Valencia in a move, which places the firm in an “unparalleled position,”​ according to the firm’s chief strategy and innovation officer.

“Our new Valencia facility will feature leading-edge technology and dramatically enhance our ability to meet fast-growing demand for products and solutions from nature designed to target the microbiome and help improve metabolic health,” ​says Ian Pinner, who is also the president of ADM’s Health & Wellness division.

“Consumers today are increasingly focusing on the foundational role food plays in supporting health and wellness, and our continued investment in these growth areas ensures that ADM is perfectly positioned to meet their needs.”

Meeting gut demand

In a statement, ADM says the facility will produce a number of probiotics and postbiotics — using ADM technology — to meet growing demand for new solutions for healthy weight management, skin health, immune health, gut health, oral health, fertility among other areas.

In response to increasing demand for microbiome-focused products, the firm’s activities within this space include the acquisition of Probiotics International Limited--known under its umbrella brand Protexin.

The UK-based manufacturer of natural healthcare and probiotic supplements for human, pet and production-animal use was purchased in a €155m (£185m) deal back in August 2018.

Prior to this, ADM took control of Biopolis – a provider of microbial technologies – in a deal that saw them acquire 90% of the shares of the Valencia-based company.

ADM’s confidence in its probiotic supplements were put to the test earlier this year with a clinical trial looking into the effects of using a food supplement containing live microbial strains in high risk COVID-19 patients.

Here, Gasteel Plus, a live microbial probiotic-based food supplement formulated using ADM probiotic strains (Bifidobacterium longum​ CECT7347, Bifidobacterium animalis subsp. lactis​ CECT9950 and Lactobacillus rhamnosus ​CNCM-I4036) as well as nutrients vitamin D, selenium and zinc, were selected in this interventional trial.

Working with the Hospital de Sagunto, the trial, which commenced in March 2020, had more than 75 subjects at the last count participating in the trial.

Botanicals, oils and fibres

“More than 75 patients admitted to the hospital with COVID-19 have already been enrolled in the trial, and are giving regular blood, stool, urine and nasopharyngeal exudate samples to measure changes in immune parameters and other factors such as viral load,”​ said Dr Xavier Cortés, gastroenterologist at Hospital de Sagunto.

“Using these indicators, we will assess the efficacy of Gasteel Plus as an adjunct solution to support the health of the elderly population, who are especially vulnerable to this viral infection.”

“We aim to expand the reach of this study to 100 patients, while exploring the potential beneficial effects of additional ingredients such as botanical extracts, oils and fibres in separate pre-clinical studies,”​ added Francisco Climent, ADM’s health & wellness managing director, EMEAI.

“Through this research, we hope to create more unique blends of our health and wellness ingredients that may help support the health of those for whom COVID-19 poses the greatest threat.”

Related news

Related products

show more

Innovation in Postbiotics and Immunity Effects

Innovation in Postbiotics and Immunity Effects

Morinaga Milk Industry Co., Ltd. | 13-Jan-2023 | Technical / White Paper

With increased research that supports the link between human health and gut microbiome, postbiotics are an emerging supplement or ingredient that is beneficial...

Give joint health consumers what they want

Give joint health consumers what they want

Lonza | 12-Jan-2023 | Technical / White Paper

It’s no secret the pandemic had a profound effect on the way we live and move. Consumers of all ages now want to get back to doing the things they love,...

Elasderma: Patented advance in molecule technology

Elasderma: Patented advance in molecule technology

Nutraceuticals Group | 05-Jan-2023 | Technical / White Paper

From Atlantic Cod, Elasderma is fully water soluble, additive free and a hydrolyzed form of Elastin that contains verifiable and quantitative levels of...

Related suppliers

Follow us


View more